Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in mice
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
It is generally believed that shutting down the kinase activity of BCR-ABL by imatinib will completely inhibit its functions, leading to inactivation of its downstream signaling pathways and cure of the disease. Imatinib is highly effective at treating human Philadelphia chromosome-positive (Ph + ) chronic myeloid leukemia (CML) in chronic phase but not Ph + B cell acute lymphoblastic leukemia (B-ALL) and CML blast crisis. We find that SRC kinases activated by BCR-ABL remain fully active in imatinib-treated mouse leukemic cells, suggesting that imatinib does not inactivate all BCR-ABL-activated signaling pathways. This SRC pathway is essential for leukemic cells to survive imatinib treatment and for CML transition to lymphoid blast crisis. Inhibition of both SRC and BCR-ABL kinase activities by dasatinib affords complete B-ALL remission. However, curing B-ALL and CML mice requires killing leukemic stem cells insensitive to both imatinib and dasatinib. Besides BCR-ABL and SRC kinases, stem cell pathways must be targeted for curative therapy of Ph + leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.
Goodell, M. A., Brose, K., Paradis, G., Conner, A. S., & Mulligan, R. C. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1797 · Cited by 2,903
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Self-citationDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485
Graham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Pear, W. S., Miller, J. P., Xu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., Bronson, R., Aster, J. C., Scott, M. L., et al. (1998) · Blood · doi:10.1182/blood.v92.10.3780 · Cited by 755
Cited by
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Zhao, C., Chen, A., Jamieson, C. H., Fereshteh, M., Abrahamsson, A., Blum, J., Kwon, H. Y., Kim, J., Chute, J. P., Rizzieri, D., et al. (2009) · Nature · doi:10.1038/nature07737 · Cited by 869
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás-Cardama, A., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 745
Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo
Zhao, C., Blum, J., Chen, A., Kwon, H. Y., Jung, S. H., Cook, J. M., Lagoo, A., & Reya, T. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.003 · Cited by 592
TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Naka, K., Hoshii, T., Muraguchi, T., Tadokoro, Y., Ooshio, T., Kondo, Y., Nakao, S., Motoyama, N., & Hirao, A. (2010) · Nature · doi:10.1038/nature08734 · Cited by 583
Hedgehog beyond medulloblastoma and basal cell carcinoma
Teglund, S., & Toftgård, R. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.01.003 · Cited by 426
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Janes, M. R., Limon, J. J., So, L., Chen, J., Lim, R. J., Chavez, M. A., Vu, C., Lilly, M. B., Mallya, S., Ong, S. T., et al. (2010) · Nature Medicine · doi:10.1038/nm.2091 · Cited by 337
Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., Sala-Torra, O., Radich, J. P., & Passegué, E. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.012 · Cited by 335
“…Cancer Cell 20, 661–673, November 15, 2011 ª2011 Elsevier Inc. stem cell (HSC) enriched Lin /Sca-1+/ c-Kit+ (LSK) fraction of the BM (Hu et al., 2006), and that developmental pathways controlling HSC function are essential for CML-LSCs generation and CML development (Warr et al.,…”
BackgroundMimeault, M., & Batra, S. K. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12004 · Cited by 330
Pushing the limits of targeted therapy in chronic myeloid leukaemia
O'Hare, T., Zabriskie, M. S., Eiring, A. M., & Deininger, M. W. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3317 · Cited by 304
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
Chen, Y., Hu, Y., Zhang, H., Peng, C., & Li, S. (2009) · Nature Genetics · doi:10.1038/ng.389 · Cited by 293
Self-citationSaito, Y., Chapple, R. H., Lin, A., Kitano, A., & Nakada, D. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.08.019 · Cited by 273
Rainey, M. D., Charlton, M. E., Stanton, R. V., & Kastan, M. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0763 · Cited by 266
Milojkovic, D., & Apperley, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1068 · Cited by 265
Differential regulation of myeloid leukemias by the bone marrow microenvironment
Krause, D. S., Fulzele, K., Catic, A., Sun, C. C., Dombkowski, D., Hurley, M. P., Lezeau, S., Attar, E., Wu, J. Y., Lin, H. Y., et al. (2013) · Nature Medicine · doi:10.1038/nm.3364 · Cited by 260
Daver, N., Thomas, D., Ravandi, F., Cortes, J., Garris, R., Jabbour, E., Garcia-Manero, G., Borthakur, G., Kadia, T., Rytting, M., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.118588 · Cited by 231
“BCRABL independent mechanisms that are known to induce resistance include reduced bioavailability of imatinib within Ph cells and activation of alternative signaling pathways that promote cell survival and proliferation such as Src-kinase pathways.(47,48) The 2-generation TKIs are capable of overcoming resistance to i…”
BackgroundMimeault, M., Hauke, R., Mehta, P. P., & Batra, S. K. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00088.x · Cited by 212
Chan, W. W., Wise, S. C., Kaufman, M. D., Ahn, Y. M., Ensinger, C. L., Haack, T., Hood, M. M., Jones, J., Lord, J. W., Lu, W. P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.003 · Cited by 208
“The CML-like MPN arises from hematopoietic stem cells (Hu et al., 2006), and is transplantable (Li et al., 1999) and responsive to TKI therapy (Hu et al., 2004).”
BackgroundInfluentialApperley, J. F., Cortes, J. E., Kim, D.-W., Roy, L., Roboz, G. J., Rosti, G., Bullorsky, E. O., Abruzzese, E., Hochhaus, A., Heim, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3339 · Cited by 194
“In a mouse model of acute leukemia, SFKs LYN, HCK, and FGR, activated by BCR-ABL in lymphoid leukemic cells, were required for CML progression to lymphoidblast crisis and development of Ph-positive ALL.(13) In this model, simultaneous inhibition of both BCR-ABL and SFK activity by dasatinib, but not sole inhibition of…”
BackgroundWelner, R. S., Amabile, G., Bararia, D., Czibere, A., Yang, H., Zhang, H., Pontes, L. L. D. F., Ye, M., Levantini, E., Di Ruscio, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.004 · Cited by 129
Leukemia stem cells in a genetically defined murine model of blast-crisis CML.
Neering, S. J., Bushnell, T., Sozer, S., Ashton, J., Rossi, R. M., Wang, P.-Y., Bell, D. R., Heinrich, D., Bottaro, A., & Jordan, C. T. (2007) · Blood · doi:10.1182/blood-2007-02-073031 · Cited by 129
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.018 · Cited by 105
BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.
Schemionek, M., Elling, C., Steidl, U., Bäumer, N., Hamilton, A., Spieker, T., Göthert, J. R., Stehling, M., Wagers, A., Huettner, C. S., et al. (2010) · Blood · doi:10.1182/blood-2009-04-215376 · Cited by 80
Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia
Signer, R. A. J., Montecino-Rodriguez, E., Witte, O. N., McLaughlin, J., & Dorshkind, K. (2007) · Blood · doi:10.1182/blood-2007-01-069401 · Cited by 77
Shi, P., Chandra, J., Sun, X., Gergely, M., Cortes, J. E., Garcia‐Manero, G., Arlinghaus, R. B., Lai, R., & Amin, H. M. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00795.x · Cited by 24
Metadata
- Authors
- Hu, Y., Swerdlow, S., Duffy, T. M., Weinmann, R., Lee, F. Y., & Li, S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-11-07
- Volume
- 103
- Issue
- 45
- Pages
- 16870-16875
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1970154345
- Cited by
- 271
- References
- 29
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.